Interim Management Statement
PIPELINE HIGHLIGHTS
LentiVector® platform
Ocular programmes (gene-based therapies targeting vision loss): partnered with Sanofi
· First RetinoStat® Phase I results (n=6) presented at 2012 ARVO Annual Meeting on Monday, 7 May 2012 indicate sustained, dose-related protein expression in the eye
· Early data show a clear dose response1, with the 10-fold escalation to dose level 2 (n=3) yielding a similar increase in average protein expression
ProSavin® (gene-based therapy for Parkinson's disease): development update
· Phase I/II study successfully met primary endpoints: ProSavin® is safe, well-tolerated and mediates long-term improvement of motor function, announced in April 2012
· Summary of data to be presented at the ASGCT 15th Annual Meeting on Thursday, 17 May 2012
5T4 tumour antigen platform
TroVax® (therapeutic cancer vaccine): publication in Lung Cancer
· Article entitled "Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma" published in Lung Cancer in April 2012 which underpins the upcoming sponsored Phase II study for TroVax® in mesothelioma